We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+56.31%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$117M
AUM Growth
+$15.6M
Cap. Flow
+$1.11M
Cap. Flow %
0.95%
Top 10 Hldgs %
40.03%
Holding
80
New
28
Increased
7
Reduced
10
Closed
27

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$3.86M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$2.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$2.35M
4
MOR
MorphoSys AG American Depositary Shares
MOR
+$2.29M
5
CRBP icon
Corbus Pharmaceuticals
CRBP
+$2.17M

Top Sells

Rank Stock Value
1
IMGN
Immunogen Inc
IMGN
+$5.54M
2
INBX
Inhibrx, Inc. Common Stock
INBX
+$2.78M
3
GPCR icon
Structure Therapeutics
GPCR
+$2.78M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$2.75M
5
LEGN icon
Legend Biotech
LEGN
+$2.28M

Sector Composition

Rank Sector Weight
1 Healthcare 98.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGMT icon
51
Sagimet Biosciences
SGMT
$439M
$330K 0.28%
+60,900
New +$437K
PACB icon
52
Pacific Biosciences
PACB
$435M
$282K 0.24%
75,300
– –
TECX
53
Tectonic Therapeutic
TECX
$529M
$78.3K 0.07%
+5,095
New +$80.7K
APLS
54
DELISTED
Apellis Pharmaceuticals
APLS
– –
-7,249
Closed -$434K
BHVN icon
55
Biohaven
BHVN
$2.03B
– –
-45,467
Closed -$1.95M
CABA icon
56
Cabaletta Bio
CABA
$437M
– –
-46,700
Closed -$1.06M
CPRX
57
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-105,500
Closed -$1.77M
ESTA icon
58
Establishment Labs
ESTA
$2.72B
– –
-27,600
Closed -$715K
EYPT icon
59
EyePoint Inc
EYPT
$1.03B
– –
-26,400
Closed -$610K
GPCR icon
60
Structure Therapeutics
GPCR
$3.41B
– –
-68,100
Closed -$2.78M
IGMS
61
DELISTED
IGM Biosciences
IGMS
– –
-135,596
Closed -$1.13M
IMTX icon
62
Immatics
IMTX
$1.18B
– –
-129,900
Closed -$1.37M
LEGN icon
63
Legend Biotech
LEGN
$3.59B
– –
-37,900
Closed -$2.28M
LNTH icon
64
Lantheus
LNTH
$6.49B
– –
-29,100
Closed -$1.8M
MGNX icon
65
MacroGenics
MGNX
$235M
– –
-125,900
Closed -$1.21M
MLTX icon
66
MoonLake Immunotherapeutics
MLTX
$1.57B
– –
-9,744
Closed -$588K
PLRX icon
67
Pliant Therapeutics
PLRX
$64.4M
– –
-49,580
Closed -$898K
PRTA icon
68
Prothena Corp
PRTA
$425M
– –
-36,384
Closed -$1.32M
RCKT icon
69
Rocket Pharmaceuticals
RCKT
$340M
– –
-91,800
Closed -$2.75M
SAGE
70
DELISTED
Sage Therapeutics
SAGE
– –
-35,257
Closed -$764K
STRO icon
71
Sutro Biopharma
STRO
$401M
– –
-15,360
Closed -$659K
STTK icon
72
Shattuck Labs
STTK
$675M
– –
-223,300
Closed -$1.59M
TSHA icon
73
Taysha Gene Therapies
TSHA
$1.68B
– –
-693,300
Closed -$1.23M
VRTX icon
74
Vertex Pharmaceuticals
VRTX
$121B
– –
-3,900
Closed -$1.59M
PROC
75
DELISTED
Procaps Group, S.A. Ordinary Shares
PROC
– –
-126,901
Closed -$516K
1 2
3
4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
CA
Carson Advisory Athens, Georgia $193M AUM 14.52% 1-Year Est. Return

Exome Asset Management's Q1 2024 Portfolio in Review

As of Q1 2024, Exome Asset Management held 80 positions worth $117M, up 15% from $101M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Exome Asset Management's Q1 2024 filing shows 28 new, 7 increased, 10 reduced and 27 closed positions. Its largest new stake was Centessa Pharmaceuticals: 274,900 shares worth $3.11M. The largest sale was Immunogen Inc, an estimated $5.54M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Exome Asset Management's largest Q1 2024 buy was Centessa Pharmaceuticals: 274,900 shares worth $3.11M.
  • Exome Asset Management added most to BeOne Medicines Ltd in Q1 2024, an estimated $3.86M increase.
  • Exome Asset Management's biggest Q1 2024 reduction was Alpine Immune Sciences Inc, cutting an estimated $1.67M.
  • Exome Asset Management fully exited Immunogen Inc in Q1 2024, selling an estimated $5.54M.
  • Exome Asset Management's ten largest holdings make up 40% of its $117M portfolio in Q1 2024.
  • Exome Asset Management opened 28 new positions and closed 27 in Q1 2024.
  • Exome Asset Management's portfolio value rose 15% quarter-over-quarter to $117M.

Based on Exome Asset Management's 13F filing for Q1 2024, filed 15 May 2024.